MENU
In this issue

Cover Focus

TOP

Preclinical, Prodromal, and Dementia Stages of Alzheimer’s Disease

Identifying the correct stage of Alzheimer’s disease helps in managing risk, diagnosis, and management decisions.

Douglas W. Scharre, MD

Neuropsychologic Assessment for Neurodegeneration

What is the value of neuropsychologic assessment in neurodegenerative diseases?

Jennifer Medina, PhD; and Sarah J. Banks, PhD, ABPP-CN

TOP

Brain Imaging in Differential Diagnosis of Dementia

Imaging biomarkers hold the promise of earlier diagnosis that may lead to more effective treatment.

Mathew R. Ayers, DO; Diana Svaldi, PhD; and Liana G. Apostolova, MD, MS

Alzheimer’s Disease Biomarkers

Amyloid, tau, neurodegeneration (ATN)—where do we go from here?

Serge Gauthier, CM, CQ, MD, FRCPC; and Pedro Rosa-Neto, MD, PhD

Disclosing Risk Factors to Individuals Without Cognitive Impairment

Negative consequences of risk factor disclosure are likely to be most severe among people who are inadequately prepared to receive the information.

Joshua D. Grill, PhD

Lewy Body Dementia

The second highest cause of dementia is highly variable.

James E. Galvin, MD, MPH

TOP

Frontotemporal Dementias

Careful clinical, neuropsychologic, and imaging investigations make differential diagnosis of variants possible.

Ryan Taylor, MD; and Elizabeth Finger, MD

Neuropsychiatric Aspects of Alzheimer’s Disease

Clinically significant neuropsychiatric symptoms need evidence-based treatment.

Zahra Goodarzi, BHSc (Hon), MD, MSc, FRCPC; and Zahinoor Ismail, MD, FRCPC

Sleep Disorders & Dementia

Sleep disorders are emerging as a biomarker for prodromal dementia.

Winnie Pao, MD

Brain Health & Dementia Risk Reduction

As preventative neurology becomes possible, it is worth providing risk reduction care to those at risk of Alzheimer’s disease dementia.

Nabeel Saif BA, MS; George Sadek, BA; Sonia Bellara, MBBS; Hollie Hristov, FNP; and Richard S. Isaacson, MD

Alzheimer’s Disease Drug Development & Emerging Therapies

We must all work together to accelerate clinical trials and create meaningful new therapies for Alzheimer’s disease.

Jeffrey L. Cummings, MD, ScD; and Kate Zhong, MD

Read Issue